Motor Neuron Diseases

Etiology and Clinical Context

Disease spectrum

Motor neuron diseases are disorders primarily affecting upper motor neurons (UMNs), lower motor neurons (LMNs), or both. Amyotrophic lateral sclerosis (ALS) is the prototypic adult disorder involving progressive degeneration of motor cortex/corticospinal pathways and brainstem/spinal motor neurons. Related phenotypes include primary lateral sclerosis (predominantly UMN), progressive muscular atrophy (predominantly LMN), and progressive bulbar palsy. ALS may be sporadic or familial; genetic associations include C9orf72 repeat expansion and SOD1 variants, among others (Shakkottai & Lomen-Hoerth, 2019).

Epidemiologic context and interpretation

ALS generally presents in adulthood, while SMN1-related spinal muscular atrophy spans childhood to adult phenotypes. The assigned nervous-system chapter describes an average onset near age 56 for ALS and reports familial presentations in up to approximately 10% of cases (Shakkottai & Lomen-Hoerth, 2019). Family history and age modify the differential but do not substitute for neurologic localization or molecular testing.

Pathophysiology

ALS is biologically heterogeneous. Mechanisms implicated include protein aggregation and altered RNA processing (often TDP-43 pathology), impaired proteostasis, excitotoxicity, oxidative stress, mitochondrial dysfunction, abnormal axonal transport, and neuroinflammatory responses. Degeneration of corticospinal pathways generates spasticity and brisk reflexes; loss of anterior horn and bulbar motor neurons causes denervation, weakness, muscle wasting, and fasciculations. Respiratory impairment arises from progressive weakness of the diaphragm and accessory respiratory muscles, not primary lung parenchymal disease (Shakkottai & Lomen-Hoerth, 2019).

Degeneration, denervation, and respiratory consequences

Injury to corticospinal tracts reduces descending inhibition of spinal reflex circuits and can produce hyperreflexia, spasticity, and pathologic plantar responses (Shakkottai & Lomen-Hoerth, 2019). Anterior horn cell or bulbar motor neuron loss deprives motor units of their axonal supply, producing weakness, neurogenic muscle atrophy, fasciculations, and electrodiagnostic denervation. These processes can coexist in one patient and one examination. Diaphragmatic weakness may first appear as orthopnea, fragmented sleep, morning headaches, weak cough, or reduced respiratory reserve, even when daytime oxygen saturation appears acceptable. Nutritional decline arises through dysphagia, fatigue, reduced intake, and increased work of breathing; respiratory and nutritional interventions address distinct but interacting sources of morbidity.

Genetics, protein handling, and disease modifiers

SMA related to biallelic SMN1 dysfunction causes deficiency of survival motor neuron protein and lower motor neuron vulnerability; SMN2 copy number helps modify phenotype (Shakkottai & Lomen-Hoerth, 2019). In ALS, most cases are sporadic, but inherited variants may involve SOD1, C9orf72, TARDBP, FUS, and related pathways. Candidate pathologic processes include abnormal protein aggregation and clearance, RNA processing disturbance, excitotoxicity, mitochondrial dysfunction, and glial inflammatory responses. These are overlapping models rather than a single causal sequence for all ALS. Cognitive and behavioral changes, including frontotemporal-spectrum dysfunction, may accompany ALS and influence communication, consent, caregiving, and prognosis.

Clinical Manifestations

Manifestations and localization

Progressive asymmetric limb weakness, foot drop, loss of hand dexterity, dysarthria, dysphagia, and muscle cramps are common presentations. Coexisting UMN signs (hyperreflexia, spasticity, extensor plantar response) and LMN signs (atrophy, fasciculations, weakness) strongly suggest ALS. Sensory examination is often relatively preserved; prominent sensory loss should prompt reconsideration. Cognitive or behavioral impairment can occur, including frontotemporal dysfunction. Bulbar involvement raises aspiration and nutritional risks (Shakkottai & Lomen-Hoerth, 2019).

Distinct motor neuron phenotypes

Amyotrophic lateral sclerosis combines upper and lower motor neuron degeneration, although signs may not appear simultaneously in every region (Shakkottai & Lomen-Hoerth, 2019). Primary lateral sclerosis is predominantly an upper motor neuron syndrome and requires longitudinal observation and exclusion of mimics. Progressive muscular atrophy is predominantly lower motor neuron involvement. Spinal muscular atrophy is a genetically mediated lower motor neuron disease, particularly associated with SMN1-related pathology in classic childhood forms, and differs biologically and therapeutically from typical adult ALS. Progressive bulbar involvement manifests through dysarthria, dysphagia, tongue wasting or fasciculations, impaired secretion management, and aspiration risk. The label motor neuron disease therefore should not be used as if all forms share one molecular mechanism or treatment pathway.

Diagnostic Evaluation

Evaluation and differential diagnosis

Diagnosis is clinical, supported by electrodiagnostic evidence of active and chronic denervation and exclusion of mimics (Shakkottai & Lomen-Hoerth, 2019). EMG/nerve conduction studies help establish widespread motor neuron dysfunction; MRI and targeted laboratory studies assess structural, metabolic, or inflammatory alternatives. Conditions that may mimic ALS include cervical myelopathy, multifocal motor neuropathy, myasthenia gravis, inclusion body myositis, and selected metabolic disorders. No isolated blood test confirms typical ALS.

Diagnostic reasoning and consequences of progression

A progressive combination of UMN and LMN dysfunction across neuroanatomic regions supports ALS, but a competing explanation must be sought actively (Shakkottai & Lomen-Hoerth, 2019). Cervical cord compression may explain hyperreflexia plus segmental hand wasting; multifocal motor neuropathy may produce asymmetric weakness and conduction block without classic UMN signs; myasthenia produces fluctuating fatigability with relatively preserved sensation; primary muscle disease has a different electrodiagnostic pattern. Serial neurologic exams, targeted MRI, nerve conduction studies, EMG, and selected laboratory tests are complementary rather than individually diagnostic. Longitudinal assessment should track swallowing, weight, speech, noninvasive ventilation needs, cough effectiveness, cognition, patient goals, and functional decline—not rely on limb strength alone.

How EMG, imaging, and genetics change the differential

Needle EMG may demonstrate active denervation and chronic neurogenic motor-unit remodeling across multiple anatomic regions in ALS; findings require interpretation alongside the clinical examination, distribution, and exclusion of alternative explanations (Shakkottai & Lomen-Hoerth, 2019). Motor and sensory nerve-conduction studies help distinguish generalized motor neuron disease from treatable multifocal motor neuropathy, demyelinating neuropathy, or other peripheral disorders. Cervical MRI may be necessary when cervical myelopathy or radiculopathy could explain combined brisk reflexes and focal weakness. Sensory loss, significant ocular movement abnormalities, or marked sphincter symptoms should trigger reconsideration rather than automatic ALS labeling.

For childhood or adult spinal muscular atrophy (SMA), SMN1-related testing can establish a molecular diagnosis and inform eligibility for disease-modifying treatment (Shakkottai & Lomen-Hoerth, 2019). ALS genetic evaluation may influence family counseling, trial referral, and—in selected genotypes—eligibility for mutation-directed therapy. Do not generalize a genotype-specific treatment to sporadic ALS or all motor neuron syndromes; mutation-directed therapies should only be considered for a confirmed eligible genotype using the current product indication.

Treatment and Management

Treatment rationale and longitudinal care

Disease-modifying treatment selection depends on phenotype, genetics, eligibility, and prescribing standards; riluzole and edaravone have roles in appropriately selected ALS care, while gene-targeted therapy is limited to eligible genetically defined disease. Respiratory surveillance, noninvasive ventilation when indicated, nutritional and swallowing support, communication assistance, rehabilitation, secretion management, and goals-of-care planning remain central. Disease-modifying therapies do not replace multidisciplinary management of progressive respiratory and bulbar dysfunction (Shakkottai & Lomen-Hoerth, 2019; U.S. Food and Drug Administration, 2023).

Therapeutic mechanism and disease-specific boundaries

Riluzole is thought to modulate glutamatergic signaling implicated in ALS, although the disease involves several interacting mechanisms. Tofersen is a genotype-specific antisense therapy for eligible adults with SOD1-associated ALS; it is not a general treatment for sporadic ALS. In SMN1-associated spinal muscular atrophy, gene-directed therapies instead increase or restore functional SMN protein, a biologically distinct target. Noninvasive ventilation, cough assistance, secretion management, nutrition, communication aids, and mobility support address consequences that disease-modifying drugs do not reverse. Treatment decisions must account for disease trajectory, eligibility, patient preference, and current prescribing information (Shakkottai & Lomen-Hoerth, 2019; U.S. Food and Drug Administration, 2023).

Genotype-specific ALS treatment and withdrawn therapy

The FDA granted accelerated approval to tofersen, an intrathecal antisense oligonucleotide that reduces SOD1 messenger RNA, for adults with ALS associated with a pathogenic SOD1 mutation. A molecular diagnosis therefore changes treatment eligibility; tofersen must not be described as a general therapy for sporadic or genetically uncharacterized ALS. Its approval was based on a neurofilament-light biomarker endpoint, with confirmatory clinical benefit still under evaluation (U.S. Food and Drug Administration [FDA], 2023).

Sodium phenylbutyrate–taurursodiol (Relyvrio) should not be included in a list of routinely available ALS treatments. Its manufacturer initiated withdrawal in April 2024 after the phase 3 PHOENIX trial did not establish clinical benefit. Riluzole, other appropriate interventions, and multidisciplinary respiratory, nutrition, mobility, and communication support remain separate considerations. Disease-modifying prescriptions and genetic counseling require specialist oversight (Amylyx Pharmaceuticals, 2024).

Complications and Red Flags

Respiratory progression is a mechanistic outcome, not just a complication

Progressive diaphragmatic and bulbar denervation can produce nocturnal hypoventilation, weak cough, aspiration, secretion retention, recurrent infection, and eventually ventilatory failure even when daytime pulse oximetry appears reassuring (Shakkottai & Lomen-Hoerth, 2019). Orthopnea, morning headache, daytime somnolence, declining cough effectiveness, and serial respiratory measurements deserve attention. Management includes anticipatory shared decisions about noninvasive ventilation, airway clearance, nutrition, speech and communication support, and goals of care. These assessments are mechanistically distinct from treatment of neuromuscular junction fatigue in MG.

Clinical Reasoning Priorities

Applied case: mixed motor findings

Progressive hand atrophy and fasciculations occur alongside brisk knee reflexes and bulbar dysarthria, without prominent sensory loss. Concurrent lower motor neuron and corticospinal signs support a motor neuron process, but cervical myelopathy and motor neuropathies remain alternatives. Serial examination, electrodiagnostics, and structural imaging help avoid premature labeling. Dysphagia and morning headache require parallel swallowing and ventilatory assessment, even when walking remains preserved.

Related YourDNP Guides

For related clinical reasoning, see Myasthenia Gravis and Parkinson Disease.

• Back to Pathophysiology
• ABG Interpretation
• Pneumonia

---

---

References

Amylyx Pharmaceuticals. (2024, April 4). Amylyx Pharmaceuticals announces formal intention to remove Relyvrio/Albrioza from the market. https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-formal-intention-remove

Shakkottai, V. G., & Lomen-Hoerth, C. (2019). Nervous system disorders. In G. D. Hammer & S. J. McPhee (Eds.), Pathophysiology of disease: An introduction to clinical medicine (8th ed.). McGraw-Hill Education.

U.S. Food and Drug Administration. (2023, April 25). FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene